Investor Relations

Latest Financial Results

Q3 2019

Quarter Ended Sep 30, 2019

Latest Annual Filing

Fiscal Year Ended Dec 31, 2018

View Filing

Stock Information

Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company’s two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation of Dexmedetomidine in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents.

BioXcel Therapeutics Presentation

BioXcel Therapeutics Presentation

Download BioXcel Therapeutics Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

BioXcel Therapeutics, Inc.
555 Long Wharf Drive
12th Floor
New Haven, CT 06511
United States
T: 475-238-6837
info@bioxceltherapeutics.com

Investor Relations

Janhavi Mohite
T: 646-536-7026
jmohite@theruthgroup.com

Transfer Agent

American Stock Transfer and Trust